Analysis of Association between Interleukin-6 (IL6), Interleukin-13 (IL13) and Tumor Necrosis Factor-Alpha (TNF-alpha) Gene Polymorphisms and Genetic Susceptibility of Rheumatoid Arthritis in Kuwaiti Arab
Background: Rheumatoid arthritis (RA) is a common autoimmune disease in which a
combination of risk alleles from different susceptibility genes predisposes the
patients to develop clinical symptoms following exposure to environmental
factors. RA is a chronic and progressive disease characterized by synovial
inflammation that results in destruction in the affected joints and severe
problems in individual’s mobility. Several immune-related risk factors have
been associated with RA, these include single nucleotide polymorphisms (SNPs)
in cytokine genes. The impact of these cytokine gene polymorphisms is due to
their association either with elevated serum levels and/or variations in their
serum levels are associated with disease-onset and progression. The objective
of this study was to investigate the role of Interleukin-6 (IL6), Interleukin-13 (IL13) and Tumor necrosis factor-alpha (TNF-alpha)
gene polymorphisms in genetic susceptibility of RA in Kuwaiti patients. Methods: We have determined the genotypes of IL6 gene (-174G/C; rs1800795), IL13 gene (R130Q; rs20541) and TNF-alpha gene (-308A/G' rs1800629) polymorphisms in
192 Kuwaiti patients with RA and compared it to that in 104 healthy controls.
The diagnosis of RA was based on the American
College of Rheumatology (ACR) classification criteria. The genotypes for IL6, IL13 and
References
[1]
Kochi, Y., Suzuki, A., Yamada, R. and Yamamoto, K. (2010) Ethnogenetic Heterogeneity of Rheumatoid Arthritis-Implications for Pathogenesis. Nature Reviews Rheumatology, 6, 290-295. https://doi.org/10.1038/nrrheum.2010.23
[2]
Yamamoto, K., Okada, Y., Suzuki, A. and Kochi, Y. (2015) Genetic Studies of Rheumatoid Arthritis. Proceedings of the Japan Academy, Series B, 91, 410-422. https://doi.org/10.2183/pjab.91.410
[3]
Dieude, P. and Cornelis, F. (2005) Genetic Basis of Rheumatoid Arthritis. Joint Bone Spine, 72, 520-526. https://doi.org/10.1016/j.jbspin.2005.09.001
[4]
Perricone, C., Ceccarelli, F. and Valesini, G. (2011) An Overview on the Genetics of Rheumatoid Arthritis: A Never Ending Story. Autoimmunity Reviews, 10, 599-608. https://doi.org/10.1016/j.autrev.2011.04.021
[5]
Palomino-Morales, R., Gonzalez-Juanatey, C., Vazquez-Rodrigues, T.R., Miranda-Filloy, J.A., Llorca, J., Martin, J. and Gonzalez-Gay, M.A. (2009) Interleukin-6 Gene-174 Promoter Polymorphism Is Associated with Endothelial Dysfunction but Not with Disease Susceptibility in Patients with Rheumatoid Arthritis. Clinical and Experimental Rheumatology, 27, 964-970.
[6]
Feldmann, M., Brennen, F.M. and Maini, R.N. (1996) Rheumatoid Arthritis. Cell, 85, 619-626. https://doi.org/10.1016/S0092-8674(00)81109-5
[7]
Nishimoto, N. and Kishimoto, T. (2006) Interleukin 6: From Bench to Bedside. Nature Clinical Practice Rheumatology, 2, 619-626. https://doi.org/10.1038/ncprheum0338
[8]
Gonzalez-Juanatey, C., Llorca, J., Miranda-Filloy, J.A., et al. (2007) Endothelial Dysfunction in Psoriatic Arthritis Patients without Clinically Evident Cardiovascular Disease or Classic Atherosclerosis Risk Factors. Arthritis & Rheumatology, 57, 287-293. https://doi.org/10.1002/art.22530
[9]
Dasgupta, B., Corkill, M., Kirkham, B., Gibson, T. and Panayi, G. (1992) Serial Estimation of Interleukin-6 as a Measure of Systemic Disease in Rheumatoid Arthritis. The Journal of Rheumatology, 19, 22-25.
[10]
Kotake, S., Sato, K., Kim, K.J., et al. (1996) Interleukin-6 and Soluble Interleukin-6 Receptor in the Synovial Fluids from Rheumatoid Arthritis Patients Are Responsible for Osteoclast-Like Cell Formation. Journal of Bone and Mineral Research, 11, 88-95. https://doi.org/10.1002/jbmr.5650110113
[11]
Fishman, D., Faulds, G., Jeffery, R., et al. (1998) The Effect of Novel Polymorphisms in the Interleukin-6 (IL6) Gene on IL-6 Transcription and Plasma IL6 Levels, and an Association with Systemic-Onset Juvenile Chronic Arthritis. The Journal of Clinical Investigation, 102, 1369-1376. https://doi.org/10.1172/JCI2629
[12]
Eder, L., Chandran, V., Pellett, F., Pollock, R., Shanmugarajah, S., Rosen, C.F., Rahman, P. and Gladman, D.D. (2011) IL13 Gene Polymorphism Is a Marker for Psoriatic Arthritis among Psoriasis Patients. Annals of the Rheumatic Diseases, 70, 1594-1598. https://doi.org/10.1136/ard.2010.147421
[13]
Spadaro, A., Rinaldi, T., Riccieri, V., et al. (2002) Interleukin 13 in Synovial Fluid and Serum of Patients with Psoriatic Arthritis. Annals of the Rheumatic Diseases, 61, 174-176. https://doi.org/10.1136/ard.61.2.174
[14]
Hart, P.H., Ahern, M.J., Smith, M.D., et al. (1995) Regulatory Effects of IL13 on Synovial Fluid Macrophages and Blood Monocytes from Patients with Inflammatory Arthritis. Clinical and Experimental Immunology, 99, 331-337. https://doi.org/10.1111/j.1365-2249.1995.tb05554.x
[15]
Chang, M., Li, Y., Yan, C., et al. (2008) Variants in the 5q31 Cytokine Gene Cluster Are Associated with Psoriasis. Genes & Immunity, 9, 176-181. https://doi.org/10.1038/sj.gene.6364451
[16]
Hohler, T., Grossmann, S., Stradmann-Bellinghausen, B., Kaluza, W., Reuss, E., de Vlam, K., Veys, E. and Marker-Hermann, E. (2002) Differential Association of Polymorphisms in the TNF-alpha Region with Psoriatic Arthritis but Not Psoriasis. Annals of the Rheumatic Diseases, 61, 213-218. https://doi.org/10.1136/ard.61.3.213
[17]
Swierkot, J., Bogunia-Kubik, K., Nowak, B., Bialowas, K., Korman, L., Gebura, K., Kolossa, K., Jeka, S. and Wiland, P. (2015) Analysis of Association between Polymorphisms within Genes Coding for Tumor Necrosis Factor (TNF)-Alpha and TNF Receptors and Responsiveness to TNF-Alpha Blockers in Patients with Rheumatoid Arthritis. Joint Bone Spine, 82, 94-99. https://doi.org/10.1016/j.jbspin.2014.08.006
[18]
Bouma, G., Crusius, J.B., Oudkerk, P.M., et al. (2008) The Clinical Response to Infliximab in Rheumatoid Arthritis Is in Part Dependent on Pretreatment Tumor Necrosis Factor Alpha Expression in the Synovium. Annals of the Rheumatic Diseases, 67, 1139-1144. https://doi.org/10.1136/ard.2007.080440
[19]
Marotte, H., Maslinski, W. and Miossec, P. (2005) Circulating Tumor Necrosis Factor-Alpha Bioactivity in Rheumatoid Arthritis Patients Treated with Infliximab: Link to Clinical Response. Arthritis Research & Therapy, 7, 149-155. https://doi.org/10.1186/ar1465
[20]
Seitz, M., Wirthmuller, U., Moller, B., et al. (2007) The -308 Tumor Necrosis Factor-Alpha Gene Polymorphism Predicts Therapeutic Response to TNF (alpha)-Blockers in Rheumatoid Arthritis and Spondyloarthritis Patients. Rheumatology (Oxford), 46, 93-96. https://doi.org/10.1093/rheumatology/kel175
[21]
Arnett, F.C., Edworthy, S.M., Bloch, D.A., McShane, D.J., Fries, J.F., Cooper, N.S., et al. (1988) The American Rheumatism Association 1987 Revised Criteria for the Classification of Rheumatoid Arthritis. Arthritis & Rheumatology, 31, 315-324. https://doi.org/10.1002/art.1780310302
[22]
Prevoo, M.L., van’t Hof, M.A., Kuper, H.H., van Leeuwen, M.A., van de Putte, L.B. and van Riel, P.L. (1995) Modified Disease Activity Scores That Include Twenty-Eight-Joint Counts. Development and Validation in a Prospective Longitudinal Study of Patients with Rheumatoid Arthritis. Arthritis & Rheumatology, 38, 44-48. https://doi.org/10.1002/art.1780380107
[23]
Fransen, J., Creemers, M.C. and van Riel, P.L. (2004) Remission in Rheumatoid Arthritis: Agreement of the Disease Activity Score (DAS28) with the ARA Preliminary Remission Criteria. Rheumatology (Oxford), 43, 1252-1255. https://doi.org/10.1093/rheumatology/keh297
[24]
Pinals, R.S., Masi, A.T. and Larsen, R.A. (1981) Preliminary Criteria for Clinical Remission in Rheumatoid Arthritis. Arthritis & Rheumatology, 24, 1308-1315. https://doi.org/10.1002/art.1780241012
[25]
Conaghan, P.G., Green, M.J. and Emery, P. (1999) Established Rheumatoid Arthritis. Best Practice & Research Clinical Rheumatology, 13, 561-575. https://doi.org/10.1053/berh.1999.0046
[26]
Harris, E.D. (2001) Treatment of Active Rheumatoid Arthritis UpToDate 2001 Version 9.1. American College of Rheumatology, Atlanta, GA, USA.
[27]
Scott, D.L. and Houssien, D.A. (1996) Joint Assessment in Rheumatoid Arthritis. British Journal of Rheumatology, 35, 14-18. https://doi.org/10.1093/rheumatology/35.suppl_2.14
[28]
van Gestel, A.M., Prevoo, M.L., van’t Hoff, M.A., van Rijswijk, M.H., van de Putte, L.B. and van Riel, P.L. (1996) Development and Validation of the European League Against Rheumatism Response Criteria for Rheumatoid Arthritis. Comparison with the Preliminary American College of Rheumatology and the World Health Organization/International League against Rheumatism Criteria. Arthritis & Rheumatology, 39, 34-40. https://doi.org/10.1002/art.1780390105
[29]
American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines (2002) Guidelines for the Management of Rheumatoid Arthritis: 2002 Update. Arthritis & Rheumatology, 6, 328-346. https://doi.org/10.1002/art.10148
[30]
Sambrook, J., Fritsch, E.F. and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual. 2nd Edition, Cold Spring Harbor Laboratory Press, New York.
[31]
Schotte, H., Schiuter, B., Rust, S., et al. (2001) Interleukin-6 Promoter Polymorphism (-174 G/C) in Caucasian German Patients with Systemic Lupus Erythematosus. Rheumatology, 40, 393-400. https://doi.org/10.1093/rheumatology/40.4.393
[32]
Graves, P.E., Kabesch, M., Halonen, M., et al. (2000) A Cluster of Seven Tightly Linked Polymorphisms in the IL13 Gene Is Associated with Total Serum IgE Levels in Three Populations of White Children. Journal of Allergy and Clinical Immunology, 105, 506-513. https://doi.org/10.1067/mai.2000.104940
[33]
Alvarez-Rodriguez, L., Lopez-Hoyos, M., Carrasco-Marin, E., et al. (2012) Analysis of the rs20541 (R130Q) Polymorphism in the IL-13 Gene in Patients with Elderly-Associated Chronic Inflammatory Diseases. Rheumatologie Clinica, 8, 321-327. https://doi.org/10.1016/j.reumae.2012.07.003
[34]
Tripathi, G., Jafar, T., Mandal, K., et al. (2008) Does Cytokine Gene Polymorphism Affect Steroid Responses in Idiopathic Nephrotic Syndrome? Indian Journal of Medical Sciences, 62, 383-391. https://doi.org/10.4103/0019-5359.44017
[35]
Marinou, I., Healy, J., Mewar, D., et al. (2007) Association of Interleukin-6 and Interleukin-10 Genotypes with Radiographic Damage in Rheumatoid Arthritis Is Dependent on Autoantibody Status. Arthritis & Rheumatology, 56, 2549-2556. https://doi.org/10.1002/art.22814
[36]
Assier, E., Boissier, M.C. and Dayer, J.M. (2010) Interleukin-6: From Identification of the Cytokine to Development of Targeted Treatments. Joint Bone Spine, 77, 532-536. https://doi.org/10.1016/j.jbspin.2010.07.007
[37]
Amr, K., El-Awady, R. and Raslan, H. (2016) Assessment of the -174G/C (rs1800795) and -572G/C (rs1800796) Interleukin 6 Gene Polymorphisms in Egyptian Patients with Rheumatoid Arthritis. Macedonian Journal of Medical Sciences, 4, 574-577. https://doi.org/10.3889/oamjms.2016.110
[38]
Wielinska, J., Dratwa, M., Swierkot, J., Korman, L., et al. (2018) Interleukin 6 Gene Polymorphism Is Associated with Protein Serum Level and Disease Activity in Polish Patients with Rheumatoid Arthritis. HLA, 92, 38-41. https://doi.org/10.1111/tan.13355
[39]
Raafat-Hamad, R.M., Mohamed, S.A., Dwedar, R.A., Elkholy, Y.S. and Elgengehy, F.T. (2018) Association of Interleukin-6 and Its -174G/C Promoter Polymorphism with Clinical and Laboratory Characteristics of Non-Hepatitis C Virus Rheumatoid Arthritis Patients. Egyptian Journal of Medical Human Genetics, 19, 235-240. https://doi.org/10.1016/j.ejmhg.2017.12.004
[40]
Gaber, W., Azkalany, G.S., Gheita, T.A., Moher, A., et al. (2013) Clinical Significance of Serum Interleukin-6 and -174G/C Promoter Polymorphism in Rheumatoid Arthritis Patients. The Egyptian Rheumatologist, 35, 107-113. https://doi.org/10.1016/j.ejr.2012.11.002
[41]
Panoulas, V.F., Stavropoulos-Kalinoglou, A., Metsios, G.S., et al. (2009) Association of Interleukin-6 (IL-6) -174G/C Gene Polymorphism with Cardiovascular Disease in Patients with Rheumatoid Arthritis: The Role of Obesity and Smoking. Atherosclerosis, 204, 178-183. https://doi.org/10.1016/j.atherosclerosis.2008.08.036
[42]
de Lima, Rushansky, E., Adelino, J.E., et al. (2020) Are Key Cytokines Genetic and Serum Levels Variations Related to Rheumatoid Arthritis Clinical Severity? Gene, 722, Article ID: 144098. https://doi.org/10.1016/j.gene.2019.144098
[43]
Li, F., Xu, J., Zheng, J., et al. (2014) Association between Interleukin-6 Gene Polymorphisms and Rheumatoid Arthritis in Chinese Han Population: A Case-Control Study and a Meta-Analysis. Scientific Reports, 4, Article No. 5714. https://doi.org/10.1038/srep05714
[44]
Pawlik, A., Wrzesniewska, J., Florczak, M., et al. (2005) IL-6 Promoter Polymorphism in Patients with Rheumatoid Arthritis. Scandinavian Journal of Rheumatology, 34, 109-113. https://doi.org/10.1080/03009740510026373
[45]
Jancic, I., Arsenovic-Ranin, N., Sefik-Bukillica, M., et al. (2013) -174G/C Interleukin Gene Promoter Polymorphism Predicts Therapeutic Response to Etanercept in Rheumatoid Arthritis. Rheumatology International, 33, 1481-1486. https://doi.org/10.1007/s00296-012-2586-y
[46]
Kabesch, M., Schedel, M., Carr, D., et al. (2006) IL4/IL13 Pathway Genetics Strongly Influence Serum IgE Levels in Childhood Asthma. Journal of Allergy and Clinical Immunology, 117, 269-274. https://doi.org/10.1016/j.jaci.2005.10.024
[47]
Mascheretti, S., Hampe, J., Kuhbacher, T., et al. (2002) Pharmacogenetic Investigation of the TNF/TNF-Receptor System in Patients with Chronic Active Crohn’s Disease Treated with Infliximab. The Pharmacogenomics Journal, 2, 127-136. https://doi.org/10.1038/sj.tpj.6500091
[48]
Fonseca, J.E., Carvalho, T., Cruz, M., et al. (2005) Polymorphism at Position -308 of the Tumor Necrosis Factor Alpha Gene and Rheumatoid Arthritis Pharmacogenetics. Annals of the Rheumatic Diseases, 64, 793-794. https://doi.org/10.1136/ard.2004.028167
